Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alicia Durham

Physician Assistant Athens, TN Physician Assistant

NPI 1629301312 CMS profile 10526601

135 N Meadows Dr, Athens, TN 37303

Open in the dashboard

General payments

$2,686

155 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alicia Durham of Athens, TN is reported in the CMS Open Payments database as having received $2,686 across 155 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $509 26
2024 General $660 34
2023 General $481 27
2022 General $398 23
2021 General $638 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alicia Durham
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alicia Durham were reported at $509. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alicia Durham Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $638 $132 $37–$438 $132
2022 $398 $155 $48–$522 $149
2023 $481 $167 $52–$557 $160
2024 $660 $178 $55–$600 $164
2025 $509 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $607 31 payments
  2. Novo Nordisk Inc $589 40 payments
  3. AbbVie, Inc. $454 24 payments
  4. Pfizer Inc. $210 14 payments
  5. AstraZeneca Pharmaceuticals LP $129 9 payments
  6. ITI, Inc. $128 6 payments
  7. Axsome Therapeutics, Inc. $112 4 payments
  8. Otsuka America Pharmaceutical, Inc. $105 6 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $46 3 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $41 2 payments
  11. Other $265 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,686 155 payments
Products named General payments · program years 2021–2025
  1. Ozempic $435 26 payments
  2. RYBELSUS $419 25 payments
  3. VRAYLAR $267 14 payments
  4. MOUNJARO $239 11 payments
  5. ZEPBOUND $161 4 payments
  6. JARDIANCE $138 9 payments
  7. TRULICITY $136 10 payments
  8. COLOGUARD DNA CAPTURE REAGENTS $127 9 payments
  9. UBRELVY $125 7 payments
  10. Wegovy $121 12 payments
  11. Other $1,474 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 126 drugs

Part D claims

6,701

Median for Physician Assistant: 241

Drug cost

$462,623

Median for Physician Assistant: $4,110

Branded share of claims

19.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 64 $77,368
Eliquis Apixaban Brand 93 $68,732
Jardiance Empagliflozin Brand 81 $65,924
Farxiga Dapagliflozin Propanediol Brand 44 $43,536
Linzess Linaclotide Brand 38 $28,825
Mounjaro Tirzepatide Brand 20 $22,079
Xarelto Rivaroxaban Brand 13 $21,179
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 31 $19,280
Januvia Sitagliptin Phosphate Brand 14 $14,478
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 12 $11,188

The 10 drugs with the highest cost, of 126 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$36,492

Of which drugs: $865

Medicare patients

249

Average age 75

Services billed

889

153 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 47%
Diabetes 35%
Ischemic heart disease 26%
Chronic kidney disease 17%
Atrial fibrillation 16%
Osteoporosis 12%
Heart failure 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 55 146 $533

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $141
$141 — —
VRAYLAR
  • AbbVie, Inc. $120
$120 — —
Wegovy
  • Novo Nordisk Inc $88
$88 — —
CAPLYTA
  • ITI, Inc. $35
$35 — —
REXULTI
  • Lundbeck LLC $20
  • Otsuka America Pharmaceutical, Inc. $15
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record